Last year a UK-China research collaboration took an unexpected turn following the discovery of resistance to the ‘last resort’ antibiotic: colistin. Here Professor Timothy Walsh, Professor of Medical Microbiology at Cardiff University, describes how the global community can learn from the positive steps taken by the Chinese Government.
Antibiotic resistance is really all about people and society. We often blame antimicrobial resistance on the bug and how resistance can travel from one bug to another. But different sectors, for example farming, hospitals and communities, are all critically linked.
In a diagnosis of the global superbug threat today, economist Jim O’Neill includes a recommendation that doctors test patients to find out if their infection is bacterial before prescribing them antibiotics. MRC-funded researcher Dr Tariq Sadiq at St George’s Institute of Infection and Immunity writes here about his research to develop better diagnostic tests that will help us get these results faster so we can make better use of antibiotics. Dr Sadiq explains the need to improve diagnostics in clinics and out in hard-to-reach populations around the world to combat widespread antimicrobial resistance.
Medical advances undermined
How have we been able to make so many advances in medicine? What’s made us so successful at treating cancer and performing heart surgery? Our ability to manage one of their most serious consequences: infection.
Antibiotic resistance undermines those advances and could mean infections that we thought we had defeated, become untreatable. Global deaths from drug-resistant infections are likely to continue to increase over the coming years if we don’t find new ways to tackle them, perhaps reaching 10 million by 2050, if there is no effective action. It is estimated that nearly half of them will occur in Asia. Read more
Researchers at the MRC Clinical Trials Unit at UCL are working on projects to tackle different forms of tuberculosis (TB) with shorter treatment programmes. The STREAM project is looking at multidrug-resistant TB, the TRUNCATE project is looking at drug sensitive TB, and the SHINE project is investigating new, shorter treatments for children with TB.
Tuberculosis kills three people every minute. Treatment invariably involves a long course of drugs and the burden of disease falls hardest on low-income countries with stretched health systems. Three projects are running at the MRC Clinical Trials Unit to investigate the efficacy of shorter courses of drugs in some of the countries worst affected by TB. Read more